Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0000950170-25-045202
Filing Date
2025-03-26
Accepted
2025-03-26 16:05:50
Documents
19
Effectiveness Date
2025-03-26

Document Format Files

Seq Description Document Type Size
1 S-8 atos-20250325.htm S-8 144269
2 EX-5.1 atos-ex5_1.htm EX-5.1 19552
3 EX-23.2 atos-ex23_2.htm EX-23.2 6406
4 EX-FILING FEES atos_exfilingfees.htm   iXBRL EX-FILING FEES 30916
5 GRAPHIC img187741201_0.jpg GRAPHIC 34892
6 GRAPHIC img187741201_1.jpg GRAPHIC 34892
7 GRAPHIC gfx187741201_0.gif GRAPHIC 554
8 GRAPHIC gfx187741201_1.jpg GRAPHIC 4071
  Complete submission text file 0000950170-25-045202.txt   444046

Data Files

Seq Description Document Type Size
21 EXTRACTED XBRL INSTANCE DOCUMENT atos_exfilingfees_htm.xml XML 9932
Mailing Address 10202 5TH AVENUE NE SUITE 200 SEATTLE WA 98125
Business Address 10202 5TH AVENUE NE SUITE 200 SEATTLE WA 98125 206.588.0256
ATOSSA THERAPEUTICS, INC. (Filer) CIK: 0001488039 (see all company filings)

EIN.: 264753208 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-286119 | Film No.: 25773177
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)